Tamoxifen was first approved in 1977 and up to now remains a noteworthy therapeutic weapon to treat mainly breast cancer. However, further considerations exist regarding the tamoxifen profile. This book discusses recent research and future perspectives in the tamoxifen field. The topics discussed include tamoxifen pharmacokinetics, pharmacodynamics, adverse effects, clinical indications, therapeutic drug monitoring, autophagy mechanisms, tamoxifen topical formulation and breast cancer risk prevention, the use of tamoxifen in an oestrogen-independent manner for various neoplasms (Hepatocellular carcinoma, renal cell carcinoma, high grade glioma), mechanisms of resistance, potential role of CYP2D6, tamoxifen and antidepressants interaction in a psychiatric view, obesity influence in tamoxifen treatment, electrical pulse-mediated tamoxifen delivery, and tamoxifen in melanoma treatment.

Intermediate filaments (IFs) are among the main cytoskeleton components in most animal cells, being intermediate in diameter between microtubules and actin filaments. Vimentin is one of the large intermediate filaments (IFs) of eukaryotic cell's cytoskeleton, being the major protein in mesenchymal cells and it is frequently used as a developmental marker of cells and tissues. It may be overexpressed in several cancers, such as lung, breast, head and neck cancer, and sarcomas. Furthermore, it plays a main role in rheumatoid arthritis and Crohn's disease. Thus, this book will address main topics concerning promising therapeutic targets for intestinal fibrosis, vimentin's potential role in epithelial mesenchymal transition (EMT), the role of vimentin in rheumatoid arthritis, vimentin mechanisms and endothelial migration, and EMT and lung neoplasms. Also discussed are insights into the proteomics' field. Many reputed experts worldwide contributed to improvement of this book and it will give readers the state of art regarding vimentin and novel approaches.